Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety.

Biomol Biomed · 2026 · PMC13170712 · PMID 41778961

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

These conversions occurred in patients receiving risankizumab ( n ═ 1), secukinumab ( n ═ 2), and guselkumab ( n ═ 1); however, this change did not reach statistical significance ( P > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.